- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01334034
Safety of NNC 0123-0000-0338 in Healthy Subjects
February 28, 2017 updated by: Novo Nordisk A/S
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC 0123-0000-0338 in Healthy Subjects
This trial is conducted in Europe.
The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body), and the pharmacodynamics (the effect of the investigated drug on the body) of NNC 0123-0000-0338 as tablets in healthy subjects.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
70
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Neuss, Germany, 41460
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 53 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Male subject
- Body mass index (BMI) between 18 and 28 kg/m^2 (both inclusive)
Exclusion Criteria:
- Known or suspected hypersensitivity to trial products or related products
- Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea, vomiting, heartburn or diarrhoea) within 2 weeks prior to dosing, as judged by the trial physician
- Presence of any medical condition that may confound the results of the trial or pose an unacceptable risk to the subject by administering the trial product, as judged by the trial physician
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose levels 1-7
|
Subjects will be randomised to receive a single dose of NNC 0123-0000-0338 (tablet), at 7 escalating dose levels.
Progression to next dose level will be based on a safety evaluation.
Subjects will receive a single dose of placebo (tablet), as a comparator to NNC 0123-0000-0338 at all dose levels.
Placebo dose remains the same at all dose levels.
As an open label active comparator, a single dose of insulin glargine will be administered subcutaneously (under the skin), at all dose levels.
Insulin glargine dose remains the same at all dose levels.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of adverse events
Time Frame: from trial product administration and until completion of the dosing visit (Day 0 to Day 6)
|
from trial product administration and until completion of the dosing visit (Day 0 to Day 6)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the serum insulin concentration-time curve
Time Frame: from 0 to 120 hours after a single dose
|
from 0 to 120 hours after a single dose
|
Area under the glucose infusion rate-time curve
Time Frame: from 0 to 24 hours after a single dose
|
from 0 to 24 hours after a single dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 11, 2011
Primary Completion (Actual)
September 16, 2011
Study Completion (Actual)
September 16, 2011
Study Registration Dates
First Submitted
April 11, 2011
First Submitted That Met QC Criteria
April 11, 2011
First Posted (Estimate)
April 12, 2011
Study Record Updates
Last Update Posted (Actual)
March 1, 2017
Last Update Submitted That Met QC Criteria
February 28, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN1953-3832
- U1111-1118-2525 (Other Identifier: WHO)
- 2010-023885-38 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on NNC 0123-0000-0338
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A | Haemophilia BUnited Kingdom
-
Novo Nordisk A/SCompletedInflammation | Rheumatoid ArthritisUnited Kingdom, Romania, Poland, Denmark, Czech Republic, Hungary
-
Novo Nordisk A/SCompletedInflammation | Healthy | Rheumatoid Arthritis | Systemic Lupus ErythematosusNetherlands
-
Novo Nordisk A/SWithdrawnInflammation | Systemic Lupus ErythematosusUnited States
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia BUnited States, Canada, United Kingdom, France, Malaysia, Brazil, Croatia, Germany, Italy, Japan, Taiwan
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia BUnited States, Netherlands, Austria, Spain, Germany, Macedonia, The Former Yugoslav Republic of, Taiwan, United Kingdom, Italy, Malaysia, Thailand, France, Greece, Russian Federation, Turkey, Japan, South Africa, Romania
-
Janssen Research & Development, LLCCompletedInflammation | Crohn's DiseaseBelgium, France, Israel, Hungary, Russian Federation, Poland, Canada, United States
-
Innate PharmaCompletedInflammation | Rheumatoid ArthritisGermany
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia BUnited States, Netherlands, Germany, Macedonia, The Former Yugoslav Republic of, United Kingdom, Italy, Malaysia, Hungary, Thailand, France, Russian Federation, Turkey, Japan, South Africa, Canada
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia BUnited States, Netherlands, Austria, Spain, Germany, Macedonia, The Former Yugoslav Republic of, Taiwan, United Kingdom, Italy, Malaysia, Thailand, France, Greece, Turkey, Japan, South Africa, Romania